Xcout Intel
Ventyx Biosciences, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Ventyx Biosciences, Inc. among biotechnology companies — ranked by similarity to what Ventyx Biosciences, Inc. actually does, not by market-cap band.
Subscribe to see Ventyx Biosciences, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. Headquartered in California, the company advances a robust clinical pipeline and operates as a publicly traded enterprise.
Ventyx Biosciences, Inc. at a glance
Ventyx Biosciences, Inc. is a biotechnology company headquartered in United States. Its most recent funding round raised $27M in September 2024. Xcout tracks 14 named people at Ventyx Biosciences, Inc., including Raju Mohan (Chief Executive Officer).
Ventyx Biosciences, Inc. leadership
- Raju MohanChief Executive Officer
- John NussExecutive Officer
- Mark S. FormanExecutive Officer
- Matthew MooreExecutive Officer
- Raju MohanExecutive Officer
- Allison HulmeDirector
8 more named people on record for Ventyx Biosciences, Inc., with roles, board committees and tenure — see the full roster →
Ventyx Biosciences, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $27M | — | |
| Series B | $51M | 1 named | |
| Series B | $51M | 12 named | |
| SEC Form D filing | $57.3M | — | |
| — | $114.3M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Ventyx Biosciences, Inc. news
Top 12 Ventyx Biosciences, Inc. competitors
Ranked by semantic similarity — how close each company is to Ventyx Biosciences, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Viela Bio, Inc. is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, dedicated to the discovery, development, and commercialization of novel therapies for autoimmune and severe inflammatory diseases.
Similar biotechnology company
RAPT Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2015, the public company leverages its proprietary drug discovery platform to develop treatments for inflammatory and immunologic diseases.
Biotech
Tr1X is a private, clinical-stage biotechnology company focused on developing regulatory T cell-based products for autoimmune and inflammatory diseases. The company aims to advance Tr1-based immunotherapies to address unmet medical needs and is headquartered in San Diego, California.
Biotech
Inventisbio is a biopharmaceutical company that focuses on the discovery and development of innovative drugs for major diseases such as tumors, autoimmune diseases, and metabolic disorders. Utilizing an independent research and development platform, the company creates proprietary drug pipelines targeting oncology drivers, kinases, and autoimmune pathways to serve patients globally.
Similar biotechnology company
Expedition Therapeutics is a clinical-stage biotechnology company headquartered in San Francisco, California, developing novel oral small molecule therapies for serious inflammatory and respiratory diseases.
Similar biotechnology company
IpiNovyx Bio, Inc. is a biopharmaceutical company that discovers and develops targeted proteasome inhibitors to treat cancer, autoimmune, and inflammatory diseases. Utilizing a proprietary technology platform, the company focuses on advancing selective and reversible immunoproteasome inhibitors to create safer and more effective therapies for patients.
Similar biotechnology company
VST Bio Corp. is a leader in the development of innovative biologics to treat acute and chronic cardiovascular diseases. Headquartered in San Diego, California, the company engages in drug pipelines, patents, and clinical trials.
Similar biotechnology company
Evommune is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California, developing new treatments for immune-mediated chronic inflammatory diseases.
Similar biotechnology company
180 Life Sciences Corp. is a clinical-stage biotechnology company traded on the NASDAQ under the ticker symbol ATNF. The company is focused on developing novel treatments for inflammatory and other medical conditions, with its operations based in Palo Alto, California.
Similar biotechnology company
Koutif Therapeutics is a biotechnology company that develops therapeutic compounds to treat inflammatory diseases by inhibiting the ubiquitin degradation pathway. The company focuses on targeting Fbxo3, an E3 ligase, to promote the degradation of pro-inflammatory proteins involved in immune signaling pathways.
Biotech
Cyxone AB is a clinical-stage biotechnology company headquartered in Malmö, Sweden. It focuses on developing a new generation of disease-modifying therapies for autoimmune and autoinflammatory diseases.
Similar biotechnology company
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Ventyx Biosciences, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Ventyx Biosciences, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →